JP4620355B2 - 活性化合物の持続、不変及び独立放出のためのマトリクス - Google Patents

活性化合物の持続、不変及び独立放出のためのマトリクス Download PDF

Info

Publication number
JP4620355B2
JP4620355B2 JP2003581744A JP2003581744A JP4620355B2 JP 4620355 B2 JP4620355 B2 JP 4620355B2 JP 2003581744 A JP2003581744 A JP 2003581744A JP 2003581744 A JP2003581744 A JP 2003581744A JP 4620355 B2 JP4620355 B2 JP 4620355B2
Authority
JP
Japan
Prior art keywords
naloxone
pharmaceutical formulation
formulation according
oxycodone
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003581744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529097A (ja
Inventor
ブローグマン，ビアンカ
ムーロウ，シルケ
スピッツェルシー，クリストフ
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4620355(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10215067A external-priority patent/DE10215067A1/de
Priority claimed from DE10215131A external-priority patent/DE10215131A1/de
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2005529097A publication Critical patent/JP2005529097A/ja
Application granted granted Critical
Publication of JP4620355B2 publication Critical patent/JP4620355B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
JP2003581744A 2002-04-05 2003-04-04 活性化合物の持続、不変及び独立放出のためのマトリクス Expired - Fee Related JP4620355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10215067A DE10215067A1 (de) 2002-04-05 2002-04-05 Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A DE10215131A1 (de) 2002-04-05 2002-04-05 Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
PCT/EP2003/003541 WO2003084504A2 (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009061144A Division JP5107954B2 (ja) 2002-04-05 2009-03-13 活性化合物の持続、不変及び独立放出のためのマトリクス

Publications (2)

Publication Number Publication Date
JP2005529097A JP2005529097A (ja) 2005-09-29
JP4620355B2 true JP4620355B2 (ja) 2011-01-26

Family

ID=28676052

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2003581760A Expired - Fee Related JP4755810B2 (ja) 2002-04-05 2003-04-04 オキシコドン及びナロキソンを含有する医薬製剤
JP2003581744A Expired - Fee Related JP4620355B2 (ja) 2002-04-05 2003-04-04 活性化合物の持続、不変及び独立放出のためのマトリクス
JP2009061144A Expired - Lifetime JP5107954B2 (ja) 2002-04-05 2009-03-13 活性化合物の持続、不変及び独立放出のためのマトリクス
JP2010088165A Expired - Lifetime JP5932209B2 (ja) 2002-04-05 2010-04-06 オキシコドン及びナロキソンを含有する医薬製剤
JP2014041261A Pending JP2014129397A (ja) 2002-04-05 2014-03-04 オキシコドン及びナロキソンを含有する医薬製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003581760A Expired - Fee Related JP4755810B2 (ja) 2002-04-05 2003-04-04 オキシコドン及びナロキソンを含有する医薬製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009061144A Expired - Lifetime JP5107954B2 (ja) 2002-04-05 2009-03-13 活性化合物の持続、不変及び独立放出のためのマトリクス
JP2010088165A Expired - Lifetime JP5932209B2 (ja) 2002-04-05 2010-04-06 オキシコドン及びナロキソンを含有する医薬製剤
JP2014041261A Pending JP2014129397A (ja) 2002-04-05 2014-03-04 オキシコドン及びナロキソンを含有する医薬製剤

Country Status (33)

Country Link
US (11) US20050245483A1 (OSRAM)
EP (17) EP1492505B1 (OSRAM)
JP (5) JP4755810B2 (OSRAM)
KR (3) KR100784341B1 (OSRAM)
CN (4) CN102813654A (OSRAM)
AP (2) AP2043A (OSRAM)
AR (3) AR039378A1 (OSRAM)
AT (1) ATE418967T2 (OSRAM)
AU (2) AU2003224041B2 (OSRAM)
BR (2) BRPI0309544B8 (OSRAM)
CA (3) CA2478515C (OSRAM)
CO (2) CO5611100A2 (OSRAM)
CY (5) CY1108914T1 (OSRAM)
DE (6) DE20308436U1 (OSRAM)
DK (6) DK2425821T5 (OSRAM)
ES (7) ES2627300T3 (OSRAM)
FI (1) FI7846U1 (OSRAM)
GE (3) GEP20064022B (OSRAM)
HK (2) HK1246176A1 (OSRAM)
HU (4) HUE031668T2 (OSRAM)
IL (5) IL163990A0 (OSRAM)
LT (3) LT2425821T (OSRAM)
MA (2) MA27116A1 (OSRAM)
MX (2) MXPA04009713A (OSRAM)
NZ (1) NZ535286A (OSRAM)
PH (1) PH12018000176A1 (OSRAM)
PT (5) PT1492506E (OSRAM)
RU (3) RU2295344C2 (OSRAM)
SI (5) SI2425825T1 (OSRAM)
TN (1) TNSN04192A1 (OSRAM)
TW (3) TWI334779B (OSRAM)
WO (2) WO2003084520A2 (OSRAM)
ZA (2) ZA200407267B (OSRAM)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
BR0115382A (pt) 2000-10-30 2003-09-16 Euro Celtique Sa Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2539027C (en) * 2003-09-25 2010-02-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
PT1781260E (pt) 2004-08-13 2010-12-20 Boehringer Ingelheim Int Formulação em comprimido de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável, um método para a preparação do mesmo e sua utilização
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
AU2011202866B2 (en) * 2006-01-27 2012-06-14 Mundipharma Pty Limited Tamper resistant dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2187873T3 (pl) 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2363468C1 (ru) * 2008-04-03 2009-08-10 Сергей Константинович Судаков Применение производных налоксона и налтрексона для приготовления обезболивающих лекарственных средств
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
CN102271661A (zh) 2008-08-20 2011-12-07 德克萨斯州立大学董事会 缓释多颗粒的热熔挤出
WO2010096045A1 (en) 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
BRPI1006186A2 (pt) * 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
ES2534908T3 (es) * 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
WO2011034554A1 (en) 2009-09-17 2011-03-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
KR20130098320A (ko) 2010-08-04 2013-09-04 토마스 줄리어스 보로디 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
KR101518143B1 (ko) * 2010-08-13 2015-05-06 유로-셀티큐 에스.에이. 저장 안정성 제제를 제조하기 위한 결합제의 용도
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
HRP20151420T4 (hr) * 2010-09-30 2019-04-05 Astrazeneca Ab Kristalni konjugat naloksol-peg
EP2651415B1 (en) 2010-12-13 2020-10-07 Rite-Prep Pty Ltd. Gastric and colonic formulations and methods for making and using them
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
NO2736497T3 (OSRAM) 2011-07-29 2018-01-20
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
BR112014004789A2 (pt) * 2011-08-29 2017-03-21 Dsm Ip Assets Bv extrusor de laboratório e método para produzir produtos farmacêuticos
WO2013050539A2 (en) * 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
EP2780000B1 (en) 2011-11-17 2019-04-03 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
IN2014DN09238A (OSRAM) 2012-04-17 2015-07-10 Purdue Pharma Lp
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
NZ703394A (en) 2012-06-04 2017-01-27 Centre For Digestive Diseases Compositions and methods for treating crohn’s disease and related conditions and infections
CN108175773A (zh) 2012-07-27 2018-06-19 红山生物医药有限公司 用于结肠排空的制剂和制备制剂方法
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
MX2015007518A (es) * 2012-12-14 2016-03-01 Trevi Therapeutics Inc Metodos para tratar el prurito.
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US20160089363A1 (en) 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
US20160244459A1 (en) 2013-05-24 2016-08-25 Rhodes Technologies Opioid ketal compounds and uses thereof
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
EP3079661B1 (de) 2013-12-11 2021-05-05 Algobate AG Naloxon-monopräparat und mehrschichttablette
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
RU2016136714A (ru) 2014-03-14 2018-04-19 ОПИАНТ ФАРМАСЮТИКАЛС, Инк. Назальные готовые лекарственные формы и способы их применения
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
KR102358879B1 (ko) 2015-05-22 2022-02-08 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3352773B1 (en) 2015-09-24 2024-12-18 San Diego State University (SDSU) Foundation DBA San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3435984A4 (en) 2016-03-31 2019-11-06 SpecGx LLC MISUSE OF INFACTIOUS PHARMACEUTICAL FORMATION WITH DELAYED RELEASE
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3630190B1 (en) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
BR112019027889A2 (pt) 2017-06-30 2020-07-07 Purdue Pharma L.P. método de tratamento e formas de dosagem do mesmo
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019152002A1 (en) * 2018-01-31 2019-08-08 Dharma Laboratories LLC Non-extractable oral solid dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2019165298A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
KR20210065969A (ko) 2018-09-27 2021-06-04 핀치 테라퓨틱스 홀딩스 엘엘씨 간질 및 관련 장애를 치료하기 위한 조성물 및 방법
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
US20220378855A1 (en) 2019-12-20 2022-12-01 Persephone Biosciences, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (OSRAM) * 1960-11-29
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (OSRAM) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
FR2183546B1 (OSRAM) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
LU77339A1 (OSRAM) 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
JPS59500418A (ja) * 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ 胃腸能動作用障害を回復する方法
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA1267092A (en) 1985-02-25 1990-03-27 Martin D. Hynes Analgesic composition containing codeine
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
WO1987001282A2 (en) 1985-09-06 1987-03-12 Key Pharmaceuticals, Inc. Method and composition for providing sustained opioid antagonism
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (ja) 1991-05-29 2001-06-18 キヤノン株式会社 画像処理方法及び装置
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
ES2120451T7 (es) 1991-09-06 2009-11-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
DE69334237D1 (de) 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
WO1994006426A1 (en) 1992-09-21 1994-03-31 Qin Bo Yi Methods for identifying and using low/non-addictive opioid analgesics
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
CN1230154C (zh) * 1993-07-01 2005-12-07 欧洲凯尔特公司 缓释组合物及制备药用组合物的方法
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
ATE212224T1 (de) 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1160115C (zh) 1994-12-12 2004-08-04 奥默罗斯公司 用于抑制疼痛,炎症和痉挛的冲洗液和方法
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
MX9700850A (es) 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
CA2239301A1 (en) 1995-12-06 1997-06-12 Charles Howard Mitch Composition for treating pain
ATE240721T1 (de) 1996-03-08 2003-06-15 Nycomed Danmark As Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
EP0854884A1 (en) * 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
ES2141631T3 (es) 1997-02-14 2000-03-16 Goedecke Ag Estabilizacion del hidrocloruro de naloxon.
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
ES2263211T3 (es) 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
AU3690297A (en) 1997-07-30 1999-02-22 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es) * 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
PL343593A1 (en) * 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
US5957459A (en) 1998-04-27 1999-09-28 Chae; Myung Joo Banking card game
DE19857766A1 (de) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin
EP0960619B1 (de) 1998-05-28 2004-03-10 Krewel Meuselbach GmbH Retardiertes Schmerzmittel enthaltend Tilidin
DE29818454U1 (de) 1998-10-15 1999-01-14 Euroceltique S.A., Luxemburg/Luxembourg Opioid-Analgetikum
SE9803760D0 (sv) 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
DE19901085C2 (de) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6419595B1 (en) 1999-07-09 2002-07-16 Bridgestone Sports Co., Ltd. Solid golf ball
US6451007B1 (en) 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
AU784541B2 (en) 1999-11-29 2006-04-27 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2001068080A2 (en) 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
JP2004501094A (ja) 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法
AU2001268353A1 (en) 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
SK12822003A3 (sk) * 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030065002A1 (en) * 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
WO2002092059A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DE10131113A1 (de) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotations-Elektromotor
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
DE20220910U1 (de) 2001-08-06 2004-08-05 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
WO2003013476A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
EP1427476B1 (en) 2001-09-06 2009-03-25 Hans Gregersen Apparatus for stimulating a bodily hollow system and for measuring reactions to stimuli of such system
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2461539A1 (en) 2001-09-24 2003-04-03 Faruk S. Abuzzahab, Sr. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
WO2003073937A1 (en) 2002-03-06 2003-09-12 Euro-Celtique S.A. Analog scale for measuring pain
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
DE10215067A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
RU2222260C1 (ru) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Способ дифференцированной оценки степени функциональной активности тонкой кишки
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
CA2509259A1 (en) 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
GEP20105052B (en) 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
AU2007240873A1 (en) 2006-04-19 2007-11-01 Jill P. Smith Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
DE202006018609U1 (de) 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
MY150600A (en) 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
NO330672B1 (no) 2009-11-12 2011-06-06 Proxdynamics As Rotormekanisme for helikoptere
KR101518143B1 (ko) 2010-08-13 2015-05-06 유로-셀티큐 에스.에이. 저장 안정성 제제를 제조하기 위한 결합제의 용도

Also Published As

Publication number Publication date
EP1639997A1 (en) 2006-03-29
HK1254279A1 (en) 2019-07-19
DE17169621T1 (de) 2019-12-19
ES2608006T3 (es) 2017-04-05
DK2425821T3 (en) 2017-08-28
US20140045877A1 (en) 2014-02-13
BR0309544A (pt) 2005-02-01
JP2010180233A (ja) 2010-08-19
EP3241548A1 (en) 2017-11-08
IL163990A (en) 2010-04-29
DK2425824T5 (en) 2018-02-12
IL163990A0 (en) 2005-12-18
ZA200407317B (en) 2005-08-31
EP2319496A1 (en) 2011-05-11
CY1118921T1 (el) 2018-01-10
FI7846U1 (fi) 2008-04-28
RU2004131870A (ru) 2005-05-27
CN102813654A (zh) 2012-12-12
CA2708900A1 (en) 2003-10-16
CN1646102B (zh) 2012-08-15
RU2004130845A (ru) 2005-06-10
US10420762B2 (en) 2019-09-24
LT2425821T (lt) 2017-07-25
AR039378A1 (es) 2005-02-16
JP5932209B2 (ja) 2016-06-08
DK1492505T3 (en) 2015-08-10
TWI334779B (en) 2010-12-21
TW200408394A (en) 2004-06-01
US9555000B2 (en) 2017-01-31
AP2004003138A0 (en) 2004-09-30
US20050245556A1 (en) 2005-11-03
HUE031668T2 (en) 2017-07-28
CA2478523A1 (en) 2003-10-16
AU2003224040B2 (en) 2006-06-22
LT2425824T (lt) 2017-07-25
JP5107954B2 (ja) 2012-12-26
DK1492506T4 (en) 2016-10-03
US20140296277A1 (en) 2014-10-02
ES2627300T3 (es) 2017-07-27
SI2425825T1 (sl) 2017-05-31
EP1492506B1 (en) 2008-12-31
EP2425825B9 (en) 2017-03-01
SI2425824T1 (sl) 2017-06-30
US20180214443A1 (en) 2018-08-02
CY1119168T1 (el) 2018-02-14
AU2003224041B2 (en) 2006-07-13
ES2733051T1 (es) 2019-11-27
HK1246176A1 (en) 2018-09-07
IL182742A0 (OSRAM) 2007-07-24
HK1072367A1 (en) 2005-08-26
AP2004003137A0 (en) 2004-09-30
CN1642529A (zh) 2005-07-20
DE17154462T1 (de) 2019-12-19
DE60325567D1 (de) 2009-02-12
EP2243471A1 (en) 2010-10-27
TWI345973B (en) 2011-08-01
JP4755810B2 (ja) 2011-08-24
TNSN04192A1 (fr) 2007-03-12
CO5611093A2 (es) 2006-02-28
US8846090B2 (en) 2014-09-30
DK200700243U3 (da) 2008-01-25
ES2546010T3 (es) 2015-09-17
ES2627298T3 (es) 2017-07-27
CN1646102A (zh) 2005-07-27
WO2003084504A2 (en) 2003-10-16
EP2425824A1 (en) 2012-03-07
US20050245483A1 (en) 2005-11-03
PT1492506E (pt) 2009-03-16
CY1119120T1 (el) 2018-02-14
CA2708900C (en) 2019-06-04
ATE418967T2 (de) 2009-01-15
US20170231978A1 (en) 2017-08-17
US20170112828A1 (en) 2017-04-27
EP2316428A1 (en) 2011-05-04
US20140045878A1 (en) 2014-02-13
EP1492506B2 (en) 2016-06-29
ES2733044T1 (es) 2019-11-27
WO2003084520A2 (en) 2003-10-16
DE20308436U1 (de) 2003-09-18
CA2478515C (en) 2010-09-28
NZ535286A (en) 2007-07-27
DK2425825T3 (en) 2017-02-20
EP2425823A1 (en) 2012-03-07
KR20070006945A (ko) 2007-01-11
EP2425821B1 (en) 2017-05-10
EP2425821A1 (en) 2012-03-07
TW200403996A (en) 2004-03-16
SI2425821T1 (sl) 2017-06-30
GEP20074022B (en) 2007-01-10
CN107669681A (zh) 2018-02-09
US8846091B2 (en) 2014-09-30
US20150005335A1 (en) 2015-01-01
CA2478515A1 (en) 2003-10-16
US9655855B2 (en) 2017-05-23
KR20040098050A (ko) 2004-11-18
DK1492506T3 (da) 2009-03-16
RU2342935C2 (ru) 2009-01-10
US9907793B2 (en) 2018-03-06
AU2003224040A1 (en) 2003-10-20
KR100717591B1 (ko) 2007-05-15
RU2297225C2 (ru) 2007-04-20
PT1492505E (pt) 2015-10-06
CN100411611C (zh) 2008-08-20
KR20040098052A (ko) 2004-11-18
TWI337077B (en) 2011-02-11
EP1492505B1 (en) 2015-06-03
DK200700243U1 (da) 2007-11-09
WO2003084504A3 (en) 2004-03-11
IL200621A (en) 2016-02-29
EP2308474A1 (en) 2011-04-13
DK2425824T3 (en) 2017-08-28
AR090677A2 (es) 2014-11-26
RU2006128796A (ru) 2008-02-20
PT2425825T (pt) 2017-02-13
BR0309004A (pt) 2005-02-01
BRPI0309544B8 (pt) 2021-05-25
GEP20064022B (en) 2007-01-10
LT2425825T (lt) 2017-02-27
MXPA04009713A (es) 2005-01-11
CO5611100A2 (es) 2006-02-28
ES2320748T3 (es) 2009-05-28
CY1116640T1 (el) 2017-03-15
EP2311438A1 (en) 2011-04-20
MXPA04009714A (es) 2005-12-05
EP2308475A1 (en) 2011-04-13
JP2014129397A (ja) 2014-07-10
EP1639996A1 (en) 2006-03-29
EP2316429A1 (en) 2011-05-04
HUE027004T2 (en) 2016-08-29
SI1492506T1 (sl) 2009-04-30
IL163989A0 (en) 2005-12-18
JP2005528375A (ja) 2005-09-22
PT2425821T (pt) 2017-08-23
PH12018000176A1 (en) 2018-11-19
PT2425824T (pt) 2017-08-23
MA27249A1 (fr) 2005-03-01
DK2425821T5 (en) 2018-02-12
IL200621A0 (en) 2011-07-31
EP1492505A2 (en) 2005-01-05
HUE032529T2 (en) 2017-09-28
AU2003224041A1 (en) 2003-10-20
DE20308437U1 (de) 2003-11-13
TW200716113A (en) 2007-05-01
CY1108914T1 (el) 2014-07-02
EP2425825B1 (en) 2016-11-16
DE20321531U1 (de) 2007-11-22
JP2009167198A (ja) 2009-07-30
AP2397A (en) 2012-04-23
FIU20070322U0 (fi) 2007-08-17
EP1492506A2 (en) 2005-01-05
BRPI0309544B1 (pt) 2018-04-03
US20120108621A1 (en) 2012-05-03
GEP20084485B (en) 2008-09-25
HUE032656T2 (en) 2017-10-30
RU2295344C2 (ru) 2007-03-20
ZA200407267B (en) 2005-08-31
US20120183612A1 (en) 2012-07-19
MA27116A1 (fr) 2004-12-20
HK1166463A1 (en) 2012-11-02
ES2320748T5 (es) 2017-02-20
AR039379A1 (es) 2005-02-16
AP2043A (en) 2009-09-09
HK1072366A1 (en) 2005-08-26
EP2425824B1 (en) 2017-05-10
JP2005529097A (ja) 2005-09-29
EP3326618A1 (en) 2018-05-30
SI1492505T1 (sl) 2015-10-30
EP2425825A1 (en) 2012-03-07
WO2003084520A3 (en) 2004-03-11
KR100784341B1 (ko) 2007-12-13

Similar Documents

Publication Publication Date Title
JP4620355B2 (ja) 活性化合物の持続、不変及び独立放出のためのマトリクス
AU2006203172A1 (en) Matrix for sustained, invariant and independent release of active compounds
HK1156537A (en) Matrix for sustained, invariant and independent release of active compounds
HK1072366B (en) Matrix for sustained, invariant and independent release of active compounds
HK1156539A (en) Matrix for sustained, invariant and independent release of active compounds
HK1158055A (en) Matrix for sustained, invariant and independent release of active compounds
HK1156525A (en) Matrix for sustained, invariant and independent release of active compounds
HK1156538A (en) Matrix for sustained, invariant and independent release of active compounds
HK1092362A (en) Matrix for sustained, invariant and independant release of active compounds
HK1092360A (en) Matrix for sustained, invariant and independant release of active compounds

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100623

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101019

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101028

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131105

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4620355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees